STP 705

Drug Profile

STP 705

Alternative Names: Anti-fibrosis RNA interference therapeutic - Sirnaomic; COTSIRANIB; STP 705; STP-705LU; STP-705LV

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator General Research Laboratory; Sirnaomics
  • Developer General Research Laboratory; Sirnaomics; Xiangxue Pharmaceutical
  • Class Stem cell therapies
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; RNA interference; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertrophic scars
  • Preclinical Fibrosis; Wounds

Most Recent Events

  • 06 Feb 2017 Phase-II clinical trials in Hypertrophic scars in USA (Intradermal)
  • 12 Mar 2008 Preclinical trials in Wounds in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top